Cytek Biosciences to Engage with Investors at Key Conferences This Fall
FREMONT, Calif., Sept. 01, 2026 /CourierPR/ -- Cytek Biosciences, a leading provider of cell analysis solutions, will be actively engaging with investors at several upcoming conferences this fall. The company’s representatives, including CEO Wenbin Jiang and CFO William McCombe, will participate in discussions and presentations at key events.
At the Wells Fargo 21st Annual Healthcare Conference, CFO William McCombe will meet with investors on Tuesday, September 8, 2026, in Boston, Massachusetts. Later that month, on Wednesday, September 16, 2026, CEO Wenbin Jiang and CFO William McCombe will co-host a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York, New York. The event will take place at 9:15 a.m. Pacific Time / 12:15 p.m. Eastern Time. Interested parties can access the live and archived webcast of the Morgan Stanley event on the company’s investor section at investors.cytekbio.com.
On Thursday, September 17, 2026, CEO Wenbin Jiang and CFO William McCombe will conduct investor meetings at the Deutsche Bank’s 2026 Healthcare Summit also held in New York, New York.
Cytek Biosciences, headquartered in Fremont, California, is dedicated to advancing cell analysis tools through its patented Full Spectrum Profiling (FSP) technology. The company’s products, including the Cytek Aurora, Northern Lights, and Borealis systems, are designed to provide high-resolution, high-content, and high-sensitivity analyses. Cytek’s platform also includes the Cytek Orion reagent preparation system and the Enhanced Small Particle (ESP) detection technology.
“Cytek Biosciences is committed to engaging with our investor community and sharing our progress and vision for the future,” said Wenbin Jiang, CEO of Cytek Biosciences. “We are excited to participate in these conferences to discuss our advancements and opportunities within the cell analysis market.”
The company’s products are primarily for research use, although certain reagents are available for clinical use in China and the European Union. Cytek Biosciences will continue to use its website, LinkedIn page, and X account as channels for disseminating information to investors and the public.